Navigation Links
Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
Date:2/12/2009

It is estimated that over 400,000 people worldwide suffer from hemophilia, of which only 25% currently receive therapy. It is estimated that the market for hemophilia treatment is in excess of seven billion dollars annually. There are two types of hemophilia, hemophilia A and hemophilia B. Hemophilia A is caused by a lack of Factor VIII and hemophilia B is caused by a deficiency of Factor IX.

About Inspiration Biopharmaceuticals

Inspiration Biopharmaceuticals was founded in 2004 with the mission to revolutionize treatments for hemophilia. The Company is focused on developing products that have the potential to broaden patient access to therapy, including prophylactic use. Greater access and more frequent prophylactic therapy have been shown to reduce complications of the disease and enhance patients' long-term health and quality of life.

Underlying the Company's programs is a novel, proprietary manufacturing technology that allows a greater yield of high-quality protein. Inspiration is utilizing this technology to develop a portfolio of hemophilia and bleeding disorder products that address a $7 billion market worldwide.

Inspiration's lead product candidate IB1001, an intravenous recombinant Factor IX, has completed preclinical testing and is now entering clinical studies in the United States and is poised to enter clinical testing in Europe and Israel.


'/>"/>
SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
2. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis
8. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
9. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
10. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
11. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Presented at American Academy of Dermatology Summer ... NeoStrata today announced,findings from an ongoing 12-week ... applied LCD (coal tar) solution (Psorent(TM)) versus,calcipotriol ... psoriasis.,Specifically, results of an interim analysis reveal ...
... 30 An overwhelming number of,Americans with memory ... their,doctors despite visits within the past six months, ... participants in the Alzheimer,s Foundation of,America (AFA) National ... the results at a poster session at the ...
Cached Medicine Technology:Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis 2Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis 3Alzheimer's Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors 2Alzheimer's Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors 3
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
(Date:7/9/2014)... have found that fecal transplantation is effective and safe ... This is the result of a study led by ... Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. The ... advance of print in the American Journal of ... C. diff , has increased to epidemic proportions over ...
(Date:7/9/2014)... July 9, 2014 There has been a ... UT Southwestern Medical Center using MyChart, the online, interactive ... results, communicate with their healthcare providers, schedule appointments, and ... of patients actively using MyChart each year ... year increased more than 10-fold, according to a study ...
(Date:7/9/2014)... Allergy and Infectious Diseases (NIAID), part of the ... clinical trial of CRS3123, an investigational oral antibiotic ... C. difficile ) infection. CRS3123 (previously known as ... difficile growth while sparing normal intestinal bacteria. , ... 30 healthy men and women ages 18 to ...
(Date:7/9/2014)... , , , , ... , , , AUDIO: , ... approximately 30cm from the bullet... , , Click here for ... , , , , , ... , , , , , University of Southampton researchers, with assistance from the Ministry of ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... American Cancer Society,is looking for individuals with or without ... the battle against cancer to serve on peer,review committees ... the,organization,s research and training grants. These "stakeholders" have,often had ... had a,family member with cancer, having been a cancer ...
... will show that dental mercury uses contribute to high ... show, for the first time, that dental mercury air,emissions ... US EPA estimates, WASHINGTON, Nov.12 The U.S. ... Reform,Committee will hold a hearing on Wednesday, Nov. 14, ...
... 12 Leading health care risk,management and insurance ... for the period ended Sept. 30, 2007, including ... first nine months of the year. The ... insurance and integrated risk management products,and services for ...
... assistance services affect quality of,patient care, CHICAGO, ... is failing to provide language assistance services required,by ... with the Office for,Civil Rights of the U.S. ... was filed by the American Federation of State, ...
... French . , The Zaire species of Ebolavirus ... species. It alone is responsible for 88% of human ... 1976. It was moreover the species involved in the ... of Congo (DRC) .In spite of the mass of ...
... Nov. 12 Verus Pharmaceuticals, Inc., a,pediatric-oriented specialty pharmaceutical ... to President & Chief Executive Officer.,Prior to the promotion, ... a result of the promotion, Cam L. Garner now ... to announce this well-deserved promotion," said Cam L.,Garner. "As ...
Cached Medicine News:Health News:American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 2Health News:Environmental Impacts of Dental Mercury Focus of U.S. House Oversight Hearing Wednesday 2Health News:FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter 2Health News:FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter 3Health News:Language Assistance Lacking at Resurrection Hospitals 2Health News:Language Assistance Lacking at Resurrection Hospitals 3Health News:New genetic lineage of Ebola virus discovered in great apes 2Health News:New genetic lineage of Ebola virus discovered in great apes 3Health News:Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer 2Health News:Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer 3
... Cougar is an Anterior Spinal Implant ... elasticity approximating that of cortical bone. The ... structural requirements of anterior column support, while ... load sharing design. Incorporates an anatomic design ...
... anterior column support for single or multilevel ... L5. The system consists of one or ... are stacked to a desired height, accommodating ... Reinforced Polymer material emulates the biomechanical properties ...
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
Anterior Interbody fusion with proven clinical performance. Large hole design. Request info fda status for sale....
Medicine Products: